1. Home
  2. SAR vs CAPR Comparison

SAR vs CAPR Comparison

Compare SAR & CAPR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SAR
  • CAPR
  • Stock Information
  • Founded
  • SAR 2007
  • CAPR 2005
  • Country
  • SAR United States
  • CAPR United States
  • Employees
  • SAR N/A
  • CAPR N/A
  • Industry
  • SAR Investment Managers
  • CAPR Biotechnology: Biological Products (No Diagnostic Substances)
  • Sector
  • SAR Finance
  • CAPR Health Care
  • Exchange
  • SAR Nasdaq
  • CAPR Nasdaq
  • Market Cap
  • SAR 402.9M
  • CAPR 322.7M
  • IPO Year
  • SAR 2007
  • CAPR N/A
  • Fundamental
  • Price
  • SAR $25.24
  • CAPR $7.10
  • Analyst Decision
  • SAR Hold
  • CAPR Strong Buy
  • Analyst Count
  • SAR 4
  • CAPR 8
  • Target Price
  • SAR $24.75
  • CAPR $24.75
  • AVG Volume (30 Days)
  • SAR 112.5K
  • CAPR 1.7M
  • Earning Date
  • SAR 10-07-2025
  • CAPR 08-11-2025
  • Dividend Yield
  • SAR 11.88%
  • CAPR N/A
  • EPS Growth
  • SAR 105.87
  • CAPR N/A
  • EPS
  • SAR 2.47
  • CAPR N/A
  • Revenue
  • SAR $142,495,705.00
  • CAPR $13,392,150.00
  • Revenue This Year
  • SAR N/A
  • CAPR $16.24
  • Revenue Next Year
  • SAR $1.97
  • CAPR $328.11
  • P/E Ratio
  • SAR $10.22
  • CAPR N/A
  • Revenue Growth
  • SAR N/A
  • CAPR N/A
  • 52 Week Low
  • SAR $21.10
  • CAPR $3.98
  • 52 Week High
  • SAR $26.49
  • CAPR $23.40
  • Technical
  • Relative Strength Index (RSI)
  • SAR 52.36
  • CAPR 42.24
  • Support Level
  • SAR $25.20
  • CAPR $6.90
  • Resistance Level
  • SAR $25.59
  • CAPR $8.00
  • Average True Range (ATR)
  • SAR 0.33
  • CAPR 0.55
  • MACD
  • SAR 0.02
  • CAPR -0.02
  • Stochastic Oscillator
  • SAR 70.23
  • CAPR 7.91

About SAR Saratoga Investment Corp New

Saratoga Investment Corp is a specialty finance company that provides customized financing solutions to U.S. middle-market businesses. The Company invests in senior and unitranche leveraged loans and mezzanine debt, and, to a lesser extent, equity to provide financing for change of ownership transactions, strategic acquisitions, recapitalizations and growth initiatives in partnership with business owners, management teams and financial sponsors. Its objective is to create attractive risk-adjusted returns by generating current income and long-term capital appreciation from its debt and equity investments.

About CAPR Capricor Therapeutics Inc.

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.

Share on Social Networks: